Previous 10 | Next 10 |
DBV Technologies (NASDAQ:DBVT) is scheduled to announce FY earnings results on Thursday, March 3rd, after market close. The consensus EPS Estimate is -$0.48 (+83.7% Y/Y) and the consensus Revenue Estimate is $4.87M (-56.8% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisio...
ACR, AQN, AVAV, AVGO, BCEL, CEMI, CLLS, CLXT, COO, COST, OTCPK:CURLF, DBVT, DUOL, EGLE, ENVX, EOLS, ESTC, EVFM, FCRD, FDUS, FNKO, GPS, INMB, OTCPK:MEGEF, MRVL, NCMI, ONCY, PAYO, PBYI, SIGA, SWBI, VERI, VZIO For Seeking Alpha's full earnings season calendar, click here. For further details s...
Montrouge, France, February 24, 2022 DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmac...
Montrouge, France, February 22, 2022 DBV Technologies to Participate in Upcoming AAAAI 202 2 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced ...
Montrouge, France, February 14, 2022 DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conferenc e DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, ...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market: NYSE Euronext Paris ISIN C...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...
Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...
Shares of DBV Technologies (DBVT +13.3%) have recouped some of their losses from yesterday after the company announced a new late-stage trial for its Viaskin peanut allergy patch. The trial will evaluate a modified patch that is 50% larger than a previous version. Kempen analyst Alex Cogut to...
BiondVax Pharmaceuticals (NASDAQ:BVXV) +55% signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany. BioRestorative Therapi...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...